Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 EUR | +1.96% | -2.80% | -19.25% |
Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Sales 2023 | 4.6M 4.95M | Sales 2024 * | 4.6M 4.95M | Capitalization | 33.49M 36.07M |
---|---|---|---|---|---|
Net income 2023 | -3M -3.23M | Net income 2024 * | -6M -6.46M | EV / Sales 2023 | 9.02 x |
Net cash position 2023 * | 100K 108K | Net cash position 2024 * | 3.4M 3.66M | EV / Sales 2024 * | 6.54 x |
P/E ratio 2023 * |
-7.43
x | P/E ratio 2024 * |
-6.93
x | Employees | 63 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 68.01% |
1 day | +1.96% | ||
1 week | -2.80% | ||
Current month | -0.95% | ||
1 month | -5.80% | ||
3 months | -10.19% | ||
6 months | -11.11% | ||
Current year | -19.25% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 1.04 | +1.96% | 14,935 |
24-05-09 | 1.02 | -2.67% | 12,162 |
24-05-08 | 1.048 | -0.38% | 5,481 |
24-05-07 | 1.052 | -0.94% | 14,065 |
24-05-06 | 1.062 | -0.75% | 75,913 |
Real-time Euronext Paris, May 10, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.25% | 36.07M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ABNX Stock